LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-02 and is reviewed periodically as new material appears.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
=== United States === One entrepreneur who was quick to spot the advantages of machine-made cigarettes was James Buchanan Duke. Previously a producer of smoking tobacco only, his firm, W. Duke & Sons & Co., entered the cigarette industry in the early 1880s. After installing two Bonsack machines, Duke spent heavily on advertising and sales promotion, and by 1889 his was the largest cigarette manufacturer in the country. The new Bonsack machines were of decisive importance in the rapid, cheap manufacture of all tobacco products but one. Cigars needed slow, laborious hand rolling and were produced in hundreds of small workshops, especially in New York City. In 1890 Duke and the other four major cigarette companies combined to form the American Tobacco Company, a firm that dominated the market and used aggressive tactics on hundreds of small competitors until they sold out to the firm. It was also called the "Tobacco Trust". The trust soon expanded its operations to include cigars, smoking, chewing tobacco and snuff. Among the companies drawn into this organization were the plug manufacturers Liggett & Myers and R. J. Reynolds Tobacco Company, which at the time produced twist and flat plug, and P. Lorillard, an old-line manufacturer of snuff. By 1910 the trust produced 86% of all cigarettes produced in the United States, and 75% to 95% of other forms, but only 14% of cigars produced in the country. At the start of the 20th century, the per capita annual consumption in the U.S.
== Chemical designation == This compound belongs to a class of experimental compounds known as N-acyl-alpha-amino acids and their derivatives. These are compounds containing an alpha-amino acid (or its derivative) with an acyl group on the terminal nitrogen atom.
The U.S. National Institute of Standards and Technology investigated the collapses of the Twin Towers and 7 WTC. The investigations examined why the buildings collapsed and what fire protection measures were in place, and evaluated how fire protection systems might be improved in future construction. The investigation into the collapse of 1 WTC and 2 WTC was concluded in October 2005 and that of 7 WTC was completed in August 2008. NIST found that the fireproofing on the Twin Towers' steel infrastructures was blown off by the initial impact of the planes and that had this not occurred, the towers likely would have remained standing. A 2007 study of the north tower's collapse published by researchers at Purdue University determined that since the plane's impact had stripped off much of the structure's thermal insulation, the heat from a typical office fire would have softened and weakened the exposed girders and columns enough to initiate the collapse regardless of the number of columns cut or damaged by the impact. The director of the original investigation stated that "the towers did amazingly well. The terrorist aircraft didn't bring the buildings down; it was the fire that followed. It was proven that you could take out two-thirds of the columns in a tower and the building would still stand." The fires weakened the trusses supporting the floors, making the floors sag. The sagging floors pulled on the exterior steel columns causing the exterior columns to bow inward.
Sources: en.wikipedia.org
== Description == Cmax is the opposite of Cmin, which is the minimum (or trough) concentration that a drug achieves after dosing. The related pharmacokinetic parameter tmax is the time at which the Cmax is observed. After an intravenous administration, Cmax and tmax are closely dependent on the experimental protocol, since the concentrations are always decreasing after the dose. But after oral administration, Cmax and tmax are dependent on the extent, and the rate of drug absorption and the disposition profile of the drug. They could be used to characterize the properties of different formulations in the same subject. Short term drug side effects are most likely to occur at or near the Cmax, whereas the therapeutic effect of drug with sustained duration of action usually occurs at concentrations slightly above the Cmin. The Cmax is often measured in an effort to show bioequivalence (BE) between a generic and innovator drug product. According to the FDA, drug quality bioavailability (BA) and BE rely on pharmacokinetic measurements such as AUC and Cmax that are reflective of systemic exposure.
SPINA-GBeta is a calculated biomarker for pancreatic beta cell function. It represents the maximum amount of insulin that beta cells can produce per time-unit (e.g. in one second). The method of calculation is based on a time-discrete nonlinear feedback model of insulin-glucose homeostasis that is rooted in the MiMe-NoCoDI modeling platform for endocrine systems.
== Regenerated cellulose == Cellulose is soluble in several kinds of media, several of which are the basis of commercial technologies. These dissolution processes are reversible and are used in the production of regenerated celluloses (such as viscose and cellophane) from dissolving pulp. The most important solubilizing agent is carbon disulfide in the presence of alkali. Other agents include Schweizer's reagent, N-methylmorpholine N-oxide, and lithium chloride in dimethylacetamide. In general, these agents modify the cellulose, rendering it soluble. The agents are then removed concomitant with the formation of fibers. Cellulose is also soluble in many kinds of ionic liquids. The history of regenerated cellulose is often cited as beginning with George Audemars, who first manufactured regenerated nitrocellulose fibers in 1855. Although these fibers were soft and strong -resembling silk- they had the drawback of being highly flammable. Hilaire de Chardonnet perfected production of nitrocellulose fibers, but manufacturing of these fibers by his process was relatively uneconomical. In 1890, L.H. Despeissis invented the cuprammonium process – which uses a cuprammonium solution to solubilize cellulose – a method still used today for production of artificial silk. In 1891, it was discovered that treatment of cellulose with alkali and carbon disulfide generated a soluble cellulose derivative known as viscose. This process, patented by the founders of the Viscose Development Company, is the most widely used method for manufacturing regenerated cellulose products.
==== Absorption ==== 2C-B appears to have relatively low oral bioavailability. The time to peak levels is 2.0 to 2.4 hours. Peak levels of 2C-B have been reported to be 2.5 ng/mL with 10 mg orally, 3.3 to 4.6 ng/mL with 20 mg orally, and 5.4 to 6.4 ng/mL with 30 mg orally. The peak levels of 2C-B metabolites have also been described.
Sources: en.wikipedia.org
For decades after Libby performed the first radiocarbon dating experiments, the only way to measure the 14C in a sample was to detect the radioactive decay of individual carbon atoms. In this approach, what is measured is the activity, in number of decay events per unit mass per time period, of the sample. This method is also known as "beta counting", because it is the beta particles emitted by the decaying 14C atoms that are detected. In the late 1970s an alternative approach became available: directly counting the number of 14C and 12C atoms in a given sample, via accelerator mass spectrometry, usually referred to as AMS. AMS counts the 14C/12C ratio directly, instead of the activity of the sample, but measurements of activity and 14C/12C ratio can be converted into each other exactly. For some time, beta counting methods were more accurate than AMS, but AMS is now more accurate and has become the method of choice for radiocarbon measurements. In addition to improved accuracy, AMS has two further significant advantages over beta counting: it can perform accurate testing on samples much too small for beta counting, and it is much faster – an accuracy of 1% can be achieved in minutes with AMS, which is far quicker than would be achievable with the older technology.
=== Stool sugar chromatography === While uncommon today, chromatography can be used to separate and identify undigested sugars present in faeces. Similarly to a stool acidity test, stool sugar chromatography is primarily used to find sugar malabsorption in children due to a lack of other available testing avenues. Although lactose may be detected in the faeces of people with lactose intolerance, this test is not considered reliable enough to conclusively diagnose or exclude lactose intolerance.
A Roadside Inn (French: L'Hôtel des voyageurs de commerce ou les Suites d'une bonne cuite, literally "The Hotel for Traveling Salesmen, or the Results of Being Very Drunk") is a 1906 French silent trick film by Georges Méliès. It was sold by Méliès's Star Film Company and is numbered 843–845 in its catalogues. Méliès plays the drunk hotel guest in the film, which uses stage machinery, pyrotechnics, and substitution splices for its effects. The distinctive film set, divided in two parts to show two rooms, is similar to one Méliès employed in his later film Tunneling the English Channel (1907).
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.